Imagine building a tiny piece of human tissue where some cells are real and others are high-tech artificial bubbles. These artificial cells act like remote controls, releasing specific signals to tell the real cells how to grow or behave. It's like adding a smart operating system to a biological organ to see exactly how it reacts to a new medicine.
Pharmaceutical R&D relies heavily on animal testing and simplistic cell cultures that fail to mimic human tissue complexity, leading to high drug failure rates.
A system of bio-hybrid materials combining living cells with chemically programmable artificial cells to control tissue differentiation and function.
If you are a drug discovery firm dealing with high failure rates in animal trials — this project developed bio-hybrid 3D tissue models that reduce the necessity for animal research. This allows for more accurate testing of how drugs interact with complex human-like tissues.
If you are a therapeutics developer dealing with inefficient drug delivery — this project developed a way to evaluate drug delivery vectors for next generation biological therapeutics. This helps in refining how medicine reaches specific targets within a tissue.
If you are a tissue engineering company dealing with the inability to create complex organ structures — this project developed a method to generate tissues with distinct different regions. This enables the creation of more realistic organoid-synthetic tissues.
Based on available project data, specific pricing or cost structures for the Bio-HhOST materials are not provided.
The project focuses on creating precision engineered microscale artificial cells. Based on available project data, industrial scaling metrics are not yet specified.
Based on available project data, there is no specific information regarding patents or licensing agreements for the bio-hybrid materials.
It integrates as a replacement or supplement to animal research by providing 3D tissue models and simulations to understand disease response.
The project is active from 2024-02-01 to 2027-07-31.
The consortium is well-balanced for technology transfer, consisting of 7 partners across 6 countries. With an industry ratio of 43% (including 3 industry partners and 2 SMEs), there is a strong commercial presence alongside 4 universities, suggesting a clear path from academic research to market application.
Contact the Università degli Studi di Trento
Contact us to connect with the Bio-HhOST consortium for early access to bio-hybrid tissue models.
